Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers

A biomarker, squamous cell carcinoma technology, applied in the field of biomarkers, can solve problems such as low treatment effect

Inactive Publication Date: 2013-03-20
NAT CANCER CENT
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is known that there are patients with high therapeutic effect and patients with low therapeutic effect on chemoradiotherapy for cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers
  • Biomarkers
  • Biomarkers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] [Example 1] This example shows that the therapeutic effect of chemoradiation therapy on cancer tissue is related to the survival rate of patients.

[0053] In the Department of Gastroenterology Surgery, Tokyo Medical University Hospital, patients (37 patients) with progressive esophageal squamous cell carcinoma were treated with preoperative chemoradiation therapy, and esophagus resection was performed 4 weeks later. For chemotherapy, fluorouracil and CDDP are used, and radiotherapy uses Linac (linear accelerator) for electron beam irradiation.

[0054] In addition, chemoradiation therapy is continued for 4 weeks, continuously from the first day to the fifth day of each week. Fluorouracil (5-FU, Kyowa Fermentation Co., Ltd.) 350mg / m is administered daily 2 (Patient body surface area), CDDP (Nippon Kayaku) 5mg / m 2 (Patient's body surface area), a total of 7000mg / m were administered during the entire treatment period 2 And a total of 100mg / m 2 . In addition, 2Gy of radiation ...

Embodiment 2

[0065] [Example 2] This example shows that the therapeutic effect of chemoradiation therapy can be predicted by the biomarkers sIL6R, MIP-1β, and PAI-1.

[0066] For blood collected in advance from the above-mentioned patients with esophageal squamous cell carcinoma before chemoradiation therapy, the three biomarkers of sIL6R, MIP-1β, and PAI-1 were measured by the fluorescent microsphere analysis system Luminex (Hitachi Software) or sandwich ELISA method Things.

[0067] Measured by Luminex, a fluorescent microsphere analysis system

[0068] sIL6R was measured using Biosource’s Extracelular Luminex Kit sIL6R (product number LHR0061), MIP-1β was measured using Biosource’s ExtracelularLuminex Kit MIP-1β (product number LHC1051), and PAI-1 was measured using R&D’s PAI-1, Human, Fluorokine MAP kit (trade number LOB1359), commissioned analysis in Hitachi software.

[0069] figure 2 A and B show the concentration of sIL6R in each patient in the group of grade 1, 2, and 3. Compared with t...

Embodiment 3

[0078] [Example 3] This example shows that the biomarker of the present invention can predict the prognosis of a patient.

[0079] Regarding the sIL6R concentration measured by the fluorescent microsphere analysis system or the sandwich ELISA method in Example 2, 30 ng / ml was used as the threshold. At this time, regarding the high sIL6R population whose blood concentration is higher than the threshold value and the low sIL6R population whose blood concentration is lower than the threshold value, the graphs showing the survival rate up to 6 years or 9 years after the start of treatment are shown in Image 6 with Figure 7 in.

[0080] In the measurement performed by the fluorescent microsphere analysis system, 18 cases were determined to be high sIL6R group, and 19 cases were low sIL6R group. The 6-year survival rate is about 25% in the high sIL6R population, compared with about 90% in the low sIL6R population, which is significantly higher (P=0.0012, long-rank test). In addition,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are biomarkers for predicting the therapeutic effect of a chemoradiotherapy treatment for cancer and predicting the prognosis of a cancer patient, and a method for measuring the biomarkers. The therapeutic effect of a chemoradiotherapy treatment on cancer in a cancer vertebrate individual can be predicted by measuring the concentrations of soluble interleukin 6 receptor, MIP-1[beta] and activated plasminogen activator inhibitor in the blood that has been collected from the vertebrate before the initiation of the chemoradiotherapy treatment. By measuring the concentration of soluble interleukin 6 receptor in the blood, the prognosis of said vertebrate can be evaluated.

Description

Technical field [0001] The present invention relates to a biomarker for judging the suitability of chemoradiation therapy for cancer patients. Background technique [0002] It has been reported that in patients with adenocarcinoma and squamous cell carcinoma, the survival rate of cancer patients is improved by performing chemoradiation therapy before tumor removal surgery compared with the case of only relying on surgery (for example, see Thomas N. et al., New England Journal of Medicine, 1996 Aug, 15:462-467 and Val Gebski et al., Lancet Oncol., 2007 Mar, 8(3):226-234). However, it is known that there are patients with high therapeutic effects of chemoradiation therapy for cancer and patients with low therapeutic effects. If these patients can be discriminated before the treatment, then the treatment method for the patients can be selected. Summary of the invention [0003] The problem to be solved by the invention [0004] Therefore, the object of the present invention is to pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/68G01N33/53
CPCG01N33/57484G01N2333/8132G01N33/6869G01N2333/7155G01N2333/521G01N2800/52G01N2333/523G01N2333/5412
Inventor 本田一文山田哲司幕内洋介逢坂由昭广桥说雄
Owner NAT CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com